Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: Analysis from the national cardiovascular data registry

Circulation: Cardiovascular Interventions

Volumn 6, Issue 4, 2013, Pages 347-353

  Baklanov, Dmitri V ^a   Kim, Sunghee ^b   Marso, Steven P ^a   Subherwal, Sumeet ^b   Rao, Sunil V ^b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bivalirudin; Hemorrhage; Percutaneous coronary intervention; Radial access

Indexed keywords

HEPARIN; HIRULOG;

ADULT; AGED; ARTERIAL LINE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; FEMORAL ARTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; OPERATIVE BLOOD LOSS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RADIAL ARTERY; REGISTER; RISK ASSESSMENT; SCORING SYSTEM; SURGICAL RISK;

BIVALIRUDIN; HEMORRHAGE; PERCUTANEOUS CORONARY INTERVENTION; RADIAL ACCESS;

AGED; ANTITHROMBINS; FEMALE; HEMORRHAGE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RADIAL ARTERY; RECOMBINANT PROTEINS; REGISTRIES; RISK;

EID: 84884471323     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.000279     Document Type: Article

References (27)

1. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
2. Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ; ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol. 2008;52:1758-1768.
3. Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS; National Cardiovascular Data Registry. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. J Am Med Assoc. 2010;303: 2156-2164.
4. Pancholy S, Patel T, Sanghvi K, Thomas M, Patel T. Comparison of doorto- balloon times for primary PCI using transradial versus transfemoral approach. Catheter Cardiovasc Interv. 2010;75:991-995.
5. Rao SV, Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008;1:379-386.
6. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4:191-197.
7. Hamon M, Mehta S, Steg PG, Faxon D, Kerkar P, Rupprecht HJ, Tanguay JF, Afzal R, Yusuf S. Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. EuroIntervention. 2011;7:91-97.
8. Weintraub WS, McKay CR, Riner RN, Ellis SG, Frommer PL, Carmichael DB, Hammermeister KE, Effros MN, Bost JE, Bodycombe DP. The American College of Cardiology National Database: progress and challenges. American College of Cardiology Database Committee. J Am Coll Cardiol. 1997;29:459-465.
9. Brindis RG, Fitzgerald S, Anderson HV, Shaw RE, Weintraub WS, Williams JF. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37:2240-2245.
10. CathPCI Registry Companion Guide to Your NCDR Data Quality Report. Washington, DC: American College of Cardiology Foundation; 2008.
11. Rao SV, Kaltenbach LA, Spertus J, Krone RJ, Singh M, Peterson ED. Abstract 13479: contemporary predictors of post-procedural bleeding complications among patients undergoing percutaneous coronary intervention (PCI): Results from the National Cardiovascular Data Registry (NCDR). Circulation. 2011;124:A13479.
12. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107.
13. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat-Simul C. 2009;38:1228-34.
14. Austin PC. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J Clin Epidemiol. 2010;63:46-55.
15. Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW; HORIZONS-AMI Trial Investigators. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention. 2011;7:905-916.
16. Barthélémy O, Silvain J, Brieger D, Mercadier A, Lancar R, Bellemain- Appaix A, Beygui F, Collet JP, Costagliola D, Montalescot G. Bleeding complications in primary percutaneous coronary intervention of STelevation myocardial infarction in a radial center. Catheter Cardiovasc Interv. 2012;79:104-112.
17. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, Budaj A, Niemelä M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR; RIVAL Trial Group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409-1420.
18. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Coll Cardiol. 2003;289: 853-863.
19. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.
20. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688-696.
21. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149-1159.
22. Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, Richardt G, Berger PB, Schömig A, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3 Trial Investigators. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J. 2010;31:582-587.
23. Kumar D, Dangas G, Mehran R, Kirtane A, Bertrand M, Ebrahimi R, Guagliumi G, Brar S, Fahy M, Heller E, Moses J, Stone G. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). Am J Cardiol. 2010;106:941-945.
24. Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L; EVENT Registry Investigators, Boston, MA. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Circ Cardiovasc Interv. 2011;4:463-473.
25. Lindsey JB, Cohen DJ, Stolker JM, Meht SK, Mahoney E, Robertus K, House JA, Kennedy K, Riggs L, Rao SV, Marso SP. The impact of bivalirudin on percutaneous coronary intervention-related bleeding. EuroIntervention. 2010;6:206-213.
26. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, Ou FS, Roe MT, Peterson ED, Marso SP; National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009;2:222-229.
27. Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schömig A, Kastrati A. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012;125:1424-1431.